Is it time to complete the transition from Masaoka-Koga to TNM in thymic tumors?—the con perspective Authors: Annemarie Shepherd Published: 2026 Thymic epithelial tumors (TETs) are rare neoplasms that originate from the thymus gland and have been historically staged according to the Masaoka-Koga (MK) staging system. From its first formulation in the 1980s, the Masaoka staging system, later refined by Koga, has served as the cornerstone of clinical decision-making in TETs (1,2). It provides a biologic and prognostic framework that has guided surgical and adjuvant treatment for decades. In 2011, the International Thymic Malignancy Interest Group (ITMIG) detailed the MK classification to clarify and define terms in order to improve reproducibility and anatomical precision (3). In 2017, the emergence of the tumor nodes metastases (TNM)-based classification in the 8th edition of the TNM staging manual represented a significant evolution toward an anatomically defined, reproducible, and data-driven system (4). Based on outcomes data from more than 8,000 patients with thymic malignances, a Staging and Prognostic Factors Committee proposed staging definitions based on levels of involvement. For the various stages, particularly the T-stage, the categories clearly correlated with recurrence rates and overall survival. After the 8th edition was published, several prospective thymic databases were created around the globe. Additionally, limitations in reproducibility of the T-stage were noted (5). In 2025, the 9th edition of the TNM staging manual emerged using additional data from these international databases, which included more nonsurgical patients, increased contribution from Asia and a total of over 9,000 patients. There were slight differences proposed, particularly, in the T1, T2 and T3 categories (4,6-8). The T1 category incorporated size using 5 cm as a cut-off between T1a and T1b categories as size was noted as a predictive factor for recurrence and prognostic for overall survival. TNM offers clarity and reproducibility. By defining T categories based on discrete anatomic landmarks, TNM minimizes subjectivity. It allows pathologists and surgeons to speak a shared, measurable language and aligns thymic staging with that of other thoracic malignancies. However, despite its promise, there are practical clinical decisions, such as post-operative radiation therapy (PORT), that still rely on the MK staging system. Because of this, the complete transition to TNM must proceed carefully, guided by evidence. Our current understanding of PORT derives almost entirely from MK-based analyses (9-14). Based on these reports from large databases and pooled analyses of retrospective studies, PORT has typically been recommended for patients with positive margins after surgical resection and for patients with completely resected MK stage III–IVA thymic malignancies. PORT has historically been considered controversial in patients with MK stage II disease and is not recommended in patients with MK stage I disease. In controversial cases, other risk factors for recurrence, such as the World Health Organization (WHO) histopathologic classification and tumor size, are often considered when determining the role for PORT. Current clinical practice guidelines base adjuvant therapy recommendations on MK stages, not TNM (15-17). Mapping MK to TNM is complex, especially for early stages (Figure 1). A tumor staged T1a N0 M0 by TNM may correspond to one of 4 MK stages: MK stage I if completely encapsulated, MK stage IIA if microscopic capsular penetration is noted, MK stage IIB if microscopic invasion of mediastinal fat is present or MK stage III if invasion of mediastinal pleura is noted. In the RYTHMIC network cohort of 196 TNM stage I thymomas, 30% were MK IIA, 28% MK IIB, and 3% MK III. In this same study, the percentage of stage I tumors for which the decision to deliver PORT was made increased significantly from 4% to 27% when patients were staged from the MK system to the TNM 8th edition (18,19). Diagram illustrating the mapping from Masaoka-Koga stage to TNM stage (9th edition) thymic epithelial tumors. This diagram was reproduced from by Fang et al. (17) under CC BY-NC-ND 4.0. MK, Masaoka-Koga; SVC, superior vena cava; TNM, tumor nodes metastases. The prospective RadioRythmic trial, which randomizes patients with MK stage II or III thymoma to PORT vs. no PORT has adopted TNM in addition to MK as the stratification schema (20). The results of this study will help to clarify the role of PORT by TNM stage, but the trial is currently ongoing and the results are not anticipated to result in many years. In the interim, as we await the prospective results of TNM-based trials such as RadioRythmic, the pragmatic path forward involves dual reporting, retrospective re-staging to TNM of historical cohorts already staged with MK, and guideline harmonization. Due to the rare nature of TETs, challenging cases should be discussed with providers in high-volume centers with experience in diagnosis and treating TETs. The ITMIG offers a virtual tumor board for these purposes. In conclusion, The MK system has shaped every major clinical trial and PORT recommendation to date. TNM, while conceptually superior, lacks equivalent clinical validation. Transitioning prematurely could confuse practice recommendations and potentially compromise patient care. The time for TNM will come—but not yet. Supplementary The article’s supplementary files as Available at https://med.amegroups.com/article/view/10.21037/med-2026-1-0010/prf